

# Ventoux Biosciences Appoints Dr. Ken Lipson, PhD as Chief Scientific Officer

*Ventoux Biosciences Elevates Leadership for Dupuytren's Disease Therapies*

SAN DIEGO, CALIFORNIA, UNITED STATES, December 26, 2023

/EINPresswire.com/ -- Ventoux Biosciences, a trailblazing specialty pharmaceutical company dedicated to developing groundbreaking, first-line therapies for Dupuytren's disease, proudly welcomes Dr. Ken Lipson, PhD, as its new Chief Scientific Officer and Vice President of Corporate Strategy.

"Ken is a highly esteemed scientist whose invaluable contributions to our Dupuytren's disease drug discovery and research program, coupled with his strategic insights as a member of our Scientific Advisory Board, make him an ideal addition to our leadership team. Dr. Lipson's extensive experience in advancing drugs, from target identification through early clinical trials in fibrosis and oncology, is pivotal. This appointment underscores our commitment to advancing treatment options for this underserved, chronic, and debilitating disease," said CEO, Kurt Harrington.

With over 30 years of biotechnology and multinational pharmaceutical expertise, Dr. Lipson most recently served as the Executive Director of Drug Research at FibroGen, Inc., where his research focused on fibrotic diseases and cancer. Dr. Lipson's significant contributions are evident in more than 100 publications in peer-reviewed journals, review articles, book chapters, and patent applications. "Ken brings a wealth of knowledge and a proven track record in drug development, and we are confident that his leadership will accelerate our efforts in bringing effective therapies to patients suffering from Dupuytren's disease," added Harrington.



Ken Lipson, PhD - Chief Scientific Officer, Ventoux Biosciences

"I am very pleased to join Ventoux Biosciences to lend my expertise to a company pioneering therapeutics for a highly prevalent disease with no available medicinal agents. I look forward to working with Kurt Harrington and the team he is building to drive the company to success," stated Dr. Lipson.

For more information about Dupuytren's Disease or Ventoux Biosciences, please visit [VentouxBio.com](http://VentouxBio.com).

#### About Ventoux Biosciences

Founded in 2022 by a Dupuytren's patient with over 25 years of pharmaceutical industry experience, Ventoux Biosciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing

proprietary products to treat Dupuytren's disease and related fibroproliferative, inflammatory diseases with significant unmet medical needs. Dupuytren's disease is a chronic, large market, disease characterized by its progressive, debilitating, and often painful nature. No first-line

pharmacologic treatment options are available and surgery remains the mainstay of treatment. Ventoux Biosciences' mission is to develop life-changing, first-line, disease-modifying therapies to slow disease progression in early to moderate stages and reduce disease recurrence post-corrective procedures for severe cases.

“

Dr. Lipson's extensive experience in advancing drugs, from target identification through early clinical trials in fibrosis and oncology, is pivotal.”

*Kurt Harrington*

Kurt Harrington

Ventoux Biosciences


+1 760-621-8562

[info@ventouxbio.com](mailto:info@ventouxbio.com)

Visit us on social media:

[Facebook](#)

[LinkedIn](#)



A patient with debilitating and irreversible Dupuytren's contracture in both hands



Kurt Harrington - Founder and CEO, Ventoux Biosciences

---

This press release can be viewed online at: <https://www.einpresswire.com/article/677476672>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.